Durect Corporation (NASDAQ:DRRX) — Market Cap & Net Worth
Market Cap & Net Worth: Durect Corporation (DRRX)
Durect Corporation (NASDAQ:DRRX) has a market capitalization of $59.31 Million ($59.31 Million) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #21352 globally and #4806 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Durect Corporation's stock price $1.91 by its total outstanding shares 31054200 (31.05 Million). Also see DRRX current and non-current assets for a full breakdown of the balance sheet.
Durect Corporation Market Cap History: 2015 to 2025
Durect Corporation's market capitalization history from 2015 to 2025. Data shows change from $686.30 Million to $59.31 Million (-21.54% CAGR). Also see Durect Corporation (DRRX) cash conversion ratio for how efficiently the company converts equity into cash flow.
Index Memberships
Durect Corporation is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.67 Trillion | 0.00% | #617 of 976 |
|
NASDAQ Composite
IXIC
|
$41.95 Trillion | 0.00% | #2045 of 3165 |
Weight: Durect Corporation's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Durect Corporation Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Durect Corporation's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check latest Durect Corporation stock price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
11.47x
Durect Corporation's market cap is 11.47 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $686.30 Million | $19.12 Million | -$22.66 Million | 35.89x | N/A |
| 2016 | $416.13 Million | $14.03 Million | -$34.51 Million | 29.67x | N/A |
| 2017 | $286.26 Million | $49.17 Million | -$3.69 Million | 5.82x | N/A |
| 2018 | $150.02 Million | $18.56 Million | -$25.32 Million | 8.08x | N/A |
| 2019 | $1.18 Billion | $29.56 Million | -$20.58 Million | 39.92x | N/A |
| 2020 | $642.82 Million | $30.11 Million | -$13.43 Million | 21.35x | N/A |
| 2021 | $306.16 Million | $13.98 Million | -$36.27 Million | 21.90x | N/A |
| 2022 | $107.45 Million | $19.28 Million | -$35.33 Million | 5.57x | N/A |
| 2023 | $18.32 Million | $8.55 Million | -$27.62 Million | 2.14x | N/A |
| 2024 | $23.29 Million | $2.03 Million | -$8.32 Million | 11.47x | N/A |
Competitor Companies of DRRX by Market Capitalization
Companies near Durect Corporation in the global market cap rankings as of September 18, 2026. Review Durect Corporation (DRRX) tangible equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Durect Corporation by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #520 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #619 globally with a market cap of $44.48 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #637 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- Haleon plc (NYSE:HLN): Ranked #665 globally with a market cap of $41.22 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #520 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #619 | GALDERMA GROUP AG | NYSE:GALDY | $44.48 Billion | $38.15 |
| #637 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.10 |
| #665 | Haleon plc | NYSE:HLN | $41.22 Billion | $9.36 |
Durect Corporation Historical Marketcap From 2015 to 2025
Between 2015 and today, Durect Corporation's market cap moved from $686.30 Million to $ 59.31 Million, with a yearly change of -21.54%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $59.31 Million | +154.67% |
| 2024 | $23.29 Million | +27.12% |
| 2023 | $18.32 Million | -82.95% |
| 2022 | $107.45 Million | -64.91% |
| 2021 | $306.16 Million | -52.37% |
| 2020 | $642.82 Million | -45.53% |
| 2019 | $1.18 Billion | +686.59% |
| 2018 | $150.02 Million | -47.59% |
| 2017 | $286.26 Million | -31.21% |
| 2016 | $416.13 Million | -39.37% |
| 2015 | $686.30 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 9th, 2026 the market cap of Durect Corporation was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $59.31 Million USD |
| MoneyControl | $59.31 Million USD |
| MarketWatch | $59.31 Million USD |
| marketcap.company | $59.31 Million USD |
| Reuters | $59.31 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Durect Corporation
DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product candidate includes larsucosterol, an endogenous, orally bioavailable small molecule to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as for the treatment… Read more